318 related articles for article (PubMed ID: 25661549)
1. New medications for treatment of obesity: metabolic and cardiovascular effects.
Pucci A; Finer N
Can J Cardiol; 2015 Feb; 31(2):142-52. PubMed ID: 25661549
[TBL] [Abstract][Full Text] [Related]
2. Drug safety evaluation of naltrexone/bupropion for the treatment of obesity.
Verpeut JL; Bello NT
Expert Opin Drug Saf; 2014 Jun; 13(6):831-41. PubMed ID: 24766397
[TBL] [Abstract][Full Text] [Related]
3. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents.
Walter CP; Bleske BE; Dorsch MP
J Clin Pharm Ther; 2014 Oct; 39(5):475-84. PubMed ID: 24924286
[TBL] [Abstract][Full Text] [Related]
4. Reducing the risk of obesity: defining the role of weight loss drugs.
Ling H; Lenz TL; Burns TL; Hilleman DE
Pharmacotherapy; 2013 Dec; 33(12):1308-21. PubMed ID: 23712541
[TBL] [Abstract][Full Text] [Related]
5. Drug treatment of obesity in the cardiovascular patient.
Charakida M; Tousoulis D; Finer N
Curr Opin Cardiol; 2013 Sep; 28(5):584-91. PubMed ID: 23928924
[TBL] [Abstract][Full Text] [Related]
6. Obesity medications: what does the future look like?
Butsch WS
Curr Opin Endocrinol Diabetes Obes; 2015 Oct; 22(5):360-6. PubMed ID: 26313898
[TBL] [Abstract][Full Text] [Related]
7. A Comparison of New Pharmacological Agents for the Treatment of Obesity.
Nuffer W; Trujillo JM; Megyeri J
Ann Pharmacother; 2016 May; 50(5):376-88. PubMed ID: 26887340
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice.
Gadde KM; Pritham Raj Y
Curr Diab Rep; 2017 May; 17(5):34. PubMed ID: 28378293
[TBL] [Abstract][Full Text] [Related]
9. New and emerging drug molecules against obesity.
George M; Rajaram M; Shanmugam E
J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):65-76. PubMed ID: 24064009
[TBL] [Abstract][Full Text] [Related]
10. Pharmacotherapy of obesity: Available medications and drugs under investigation.
Pilitsi E; Farr OM; Polyzos SA; Perakakis N; Nolen-Doerr E; Papathanasiou AE; Mantzoros CS
Metabolism; 2019 Mar; 92():170-192. PubMed ID: 30391259
[TBL] [Abstract][Full Text] [Related]
11. New antiobesity agents: lorcaserin (Belviq) and phentermine/topiramate ER (Qsymia).
Shyh G; Cheng-Lai A
Cardiol Rev; 2014; 22(1):43-50. PubMed ID: 24304809
[TBL] [Abstract][Full Text] [Related]
12. Anti-obesity drugs: a review about their effects and their safety.
Derosa G; Maffioli P
Expert Opin Drug Saf; 2012 May; 11(3):459-71. PubMed ID: 22439841
[TBL] [Abstract][Full Text] [Related]
13. Pharmacotherapy for the management of obesity.
Patel D
Metabolism; 2015 Nov; 64(11):1376-85. PubMed ID: 26342499
[TBL] [Abstract][Full Text] [Related]
14. [Recent progress and novel perspectives on obesity pharmacotherapy].
Faria AM; Mancini MC; Melo ME; Cercato C; Halpern A
Arq Bras Endocrinol Metabol; 2010 Aug; 54(6):516-29. PubMed ID: 20857056
[TBL] [Abstract][Full Text] [Related]
15. Drug treatment of obesity: current status and future prospects.
Kakkar AK; Dahiya N
Eur J Intern Med; 2015 Mar; 26(2):89-94. PubMed ID: 25634851
[TBL] [Abstract][Full Text] [Related]
16. Obesity: new perspectives and pharmacotherapies.
Palamara KL; Mogul HR; Peterson SJ; Frishman WH
Cardiol Rev; 2006; 14(5):238-58. PubMed ID: 16924165
[TBL] [Abstract][Full Text] [Related]
17. Evolution of pharmacological obesity treatments: focus on adverse side-effect profiles.
Krentz AJ; Fujioka K; Hompesch M
Diabetes Obes Metab; 2016 Jun; 18(6):558-70. PubMed ID: 26936802
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy for Obesity.
Saunders KH; Shukla AP; Igel LI; Kumar RB; Aronne LJ
Endocrinol Metab Clin North Am; 2016 Sep; 45(3):521-38. PubMed ID: 27519128
[TBL] [Abstract][Full Text] [Related]
19. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
20. Update on obesity pharmacotherapy.
Bray GA; Ryan DH
Ann N Y Acad Sci; 2014 Apr; 1311():1-13. PubMed ID: 24641701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
